Journal
NATURE MEDICINE
Volume 13, Issue 12, Pages 1483-1489Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm1668
Keywords
-
Funding
- MRC [MC_U137881016] Funding Source: UKRI
- Medical Research Council [MC_U137881016] Funding Source: researchfish
- Medical Research Council [MC_U137881016] Funding Source: Medline
Ask authors/readers for more resources
Multiple sclerosis is a neuroinflammatory disease associated with axonal degeneration(1,2). The neuronally expressed, protongated acid-sensing ion channel-1 (ASIC1)(3,4) is permeable to Na+ and Ca2+, and excessive accumulation of these ions is associated with axonal degeneration(5). We tested the hypothesis that ASIC1 contributes to axonal degeneration in inflammatory lesions of the central nervous system (CNS). After induction of experimental autoimmune encephalomyelitis (EAE), Asic1(-/-) mice showed both a markedly reduced clinical deficit and reduced axonal degeneration compared to wild-type mice. Consistently with acidosis-mediated injury, pH measurements in the spinal cord of EAE mice showed tissue acidosis sufficient to open ASIC1. The acidosis-related protective effect of Asic1 disruption was also observed in nerve explants in vitro. Amiloride, a licensed and clinically safe blocker of ASICs, was equally neuroprotective in nerve explants and in EAE. Although ASICs are also expressed by immune cells, this expression is unlikely to explain the neuroprotective effect of Asic1 inactivation, as CNS inflammation was similar in wild-type and Asic1(-/-) mice. In addition, adoptive transfer of T cells from wild-type mice did not affect the protection mediated by Asic1 disruption. These results suggest that ASIC1 blockers could provide neuroprotection in multiple sclerosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available